ARROWHEAD PHARMACEUTICALS, INC. (ARWR) FY2026 Q3 Balance Sheet

Income StatementCash FlowBalance Sheet

Balance Sheet

As of 2026-06-30

Swipe to see the full flow
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) FY2026 Q3 Balance SheetBalance sheet as of 2026-06-30. The chart shows assets, liabilities and equity at that date.Current liabilities$283.35 MLiabilities(calculated)$1.65 BCurrent assets$1.67 BNon-current liabilities$1.36 BAssets$2.11 BEquity$466.04 MGross equity(calculated)$2.44 BNon-current assets$440.60 MHOLDINGSASSET CLASSASSETSCLAIM CLASSCLAIM SUB-CLASSCLAIMSAvailable-for-sale securities, at fair valueCash, cash equivalents and restricted cashOther current assetsPrepaid expensesAccounts receivableProperty, plant and equipment, netRight-of-use assetsOther assetsIntangible assets, netDeferred revenueAccrued expensesCredit facilityAccounts payableAccrued payroll and benefitsOther liabilitiesLease liabilitiesConvertible Notes, NetLiability related to the sale of future royaltiesCredit facility, net of current portionLease liabilities, net of current portionDeferred revenue, net of current portionAdditional paid-in capitalCommon stock, $0.001 par value: Authorized 290,000 shares; 143,796 shares issued and 141,135 outstanding as of June 30, 2026 and 138,363 shares issued and 135,702 outstanding as of September 30, 2025Noncontrolling interestCurrent assetsNon-current assetsAssetsCurrent liabilitiesNon-current liabilitiesLiabilities (calculated)EquityGross equity (calculated)Accumulated deficitTreasury stock; at cost; 2,661 shares of common stock at June 30, 2026 and September 30, 2025Accumulated other comprehensive (loss) incomeDeferred revenueDeferred revenue$94.60 MAccrued expensesAccrued expenses$86.17 MCurrent liabilitiesCurrent liabilities$283.35 MCredit facilityCredit facility$40.00 MAccounts payableAccounts payable$27.78 MLiabilities (calculated)Liabilities(calculated)$1.65 BAccrued payroll and benefitsAccrued payroll and benefits$23.46 MOther liabilitiesOther liabilities$6.02 MCurrent assetsCurrent assets$1.67 BLease liabilitiesLease liabilities$5.32 MNon-current liabilitiesNon-current liabilities$1.36 BAvailable-for-sale securities, at fair valueAvailable-for-sale securities, at fair value$1.55 BAssetsAssets$2.11 BConvertible Notes, NetConvertible Notes, Net$682.71 MLiability related to the sale of future royaltiesLiability related to the sale of future royalties$392.51 MCash, cash equivalents and restricted cashCash, cash equivalents and restricted cash$54.76 MCredit facility, net of current portionCredit facility, net of current portion$141.37 MOther current assetsOther current assets$35.52 MLease liabilities, net of current portionLease liabilities, net of current portion$114.30 MEquityEquity$466.04 MPrepaid expensesPrepaid expenses$25.37 MDeferred revenue, net of current portionDeferred revenue, net of current portion$31.74 MGross equity (calculated)Gross equity(calculated)$2.44 BAccounts receivableAccounts receivable$8.56 MProperty, plant and equipment, netProperty, plant and equipment, net$373.30 MNon-current assetsNon-current assets$440.60 MRight-of-use assetsRight-of-use assets$55.67 MOther assetsOther assets$6.05 MAdditional paid-in capitalAdditional paid-in capital$2.44 BIntangible assets, netIntangible assets, net$5.59 MCommon stock, $0.001 par value: Authorized 290,000 shares; 143,796 shares issued and 141,135 outstanding as of June 30, 2026 and 138,363 shares issued and 135,702 outstanding as of September 30, 2025Common stock$237.00 KNoncontrolling interestNoncontrolling interest$512.00 KAccumulated deficitAccumulated deficit−$1.92 BTreasury stock; at cost; 2,661 shares of common stock at June 30, 2026 and September 30, 2025Treasury stock−$53.19 MAccumulated other comprehensive (loss) incomeAccumulated other comprehensive (loss) income−$1.23 M
Chart details

ARROWHEAD PHARMACEUTICALS, INC. (ARWR) FY2026 Q3 Balance Sheet

Balance sheet as of 2026-06-30. The chart shows assets, liabilities and equity at that date.

Assets
2,112,013,000 US dollars
Current assets
1,671,411,000 US dollars
Non-current assets
440,602,000 US dollars
Liabilities (calculated)
1,645,972,000 US dollars
Current liabilities
283,346,000 US dollars
Non-current liabilities
1,362,626,000 US dollars
Equity
466,041,000 US dollars
Noncontrolling interest
512,000 US dollars. Included in consolidated equity; this amount is not added again.
Available-for-sale securities, at fair value
1,547,201,000 US dollars
Cash, cash equivalents and restricted cash
54,759,000 US dollars
Other current assets
35,522,000 US dollars
Prepaid expenses
25,373,000 US dollars
Accounts receivable
8,556,000 US dollars
Property, plant and equipment, net
373,301,000 US dollars
Right-of-use assets
55,667,000 US dollars
Other assets
6,048,000 US dollars
Intangible assets, net
5,586,000 US dollars
Deferred revenue
94,596,000 US dollars
Accrued expenses
86,174,000 US dollars
Credit facility
40,000,000 US dollars
Accounts payable
27,776,000 US dollars
Accrued payroll and benefits
23,455,000 US dollars
Other liabilities
6,023,000 US dollars
Lease liabilities
5,322,000 US dollars
Convertible Notes, Net
682,707,000 US dollars
Liability related to the sale of future royalties
392,512,000 US dollars
Credit facility, net of current portion
141,366,000 US dollars
Lease liabilities, net of current portion
114,298,000 US dollars
Deferred revenue, net of current portion
31,743,000 US dollars
Additional paid-in capital
2,443,074,000 US dollars
Common stock, $0.001 par value: Authorized 290,000 shares; 143,796 shares issued and 141,135 outstanding as of June 30, 2026 and 138,363 shares issued and 135,702 outstanding as of September 30, 2025
237,000 US dollars
Noncontrolling interest
512,000 US dollars
Accumulated deficit
negative 1,923,355,000 US dollars
Treasury stock; at cost; 2,661 shares of common stock at June 30, 2026 and September 30, 2025
negative 53,193,000 US dollars
Accumulated other comprehensive (loss) income
negative 1,234,000 US dollars
Gross equity (calculated)
2,443,823,000 US dollars. Net equity plus the magnitudes of its negative contributions equals gross positive equity. The negative contributions enter this reconciliation as add-backs; their filed signs stay negative.

Chart connections

  • Assets equal liabilities plus consolidated equity. Consolidated equity includes noncontrolling interests when reported.
  • Treasury shares and other negative equity contributions reduce equity.
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) FY2026 Q3 Balance Sheet Sankey chart
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG

Newsletter

Get the teardowns by email

Subscribe if you want the public-company teardowns in your inbox when they're released.

Product waitlist

Health Check and Teardown for your own company

A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!